We have also recently discovered that the domain rearrangement of bispecific Db led to substantial cytotoxic enhancement25,26, and the Fc fusion format based on the domain-rearranged variant of hEx3-Db, designated hEx3-scDb-3C-Fc-LH, also had higher in vitro and in vivo anti-tumor activity than that of the previous version27. This evidence concerns the gene PLOD1 and neoplasm.